-
Tytuł:
-
Nanocrytals-Mediated Oral Drug Delivery: Enhanced Bioavailability of Amiodarone.
-
Autorzy:
-
Awan AM; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Farid A; Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan 29050, Pakistan.
Shah SU; Skin/Regenerative Medicine and Drug Delivery Research, GCPS, Faculty of Pharmacy, Gomal University, Dera Ismail Khan 29050, Pakistan.
Khan D; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Ur Rehman F; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Dar MJ; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Iftikhar T; Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan.
Ghazanfar S; Functional Genomics and Bioinformatics, National Agricultural Research Centre, Islamabad 45500, Pakistan.
Galanakis CM; Research & Innovation Department, Galanakis Laboratories, 73131 Chania, Greece.; Food Waste Recovery Group, ISEKI Food Association, 1190 Vienna, Austria.; Department of Biology, College of Science, Taif University, Taif 26571, Saudi Arabia.
Alamri AS; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.; Centre of Biomedical Sciences Research (CBSR), Deanship of Scientific Research, Taif University, Taif 21944, Saudi Arabia.
Asdaq SMB; Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
Shah KU; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
-
Źródło:
-
Pharmaceutics [Pharmaceutics] 2022 Jun 18; Vol. 14 (6). Date of Electronic Publication: 2022 Jun 18.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Basel, Switzerland : MDPI
-
References:
-
Int J Pharm. 2021 Dec 15;610:121242. (PMID: 34737113)
Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44. (PMID: 17601629)
Int J Pharm. 2009 Jun 5;374(1-2):106-13. (PMID: 19446766)
Res Pharm Sci. 2015 Mar-Apr;10(2):95-108. (PMID: 26487886)
Drug Dev Ind Pharm. 2012 Oct;38(10):1230-9. (PMID: 22229827)
Int J Nanomedicine. 2015 Oct 12;10:6339-53. (PMID: 26491298)
Cardiovasc Drugs Ther. 2013 Apr;27(2):125-32. (PMID: 23344929)
Eur J Pharm Biopharm. 2006 Jan;62(1):3-16. (PMID: 16129588)
Int J Nanomedicine. 2016 May 27;11:2359-67. (PMID: 27313453)
Int J Pharm. 2017 Jan 10;516(1-2):372-379. (PMID: 27880871)
Chem Pharm Bull (Tokyo). 2015;63(4):295-9. (PMID: 25832024)
AAPS PharmSciTech. 2012 Mar;13(1):295-304. (PMID: 22246736)
Pharm Sci Technol Today. 2000 Apr;3(4):138-145. (PMID: 10754543)
Pharmaceutics. 2022 Mar 23;14(4):. (PMID: 35456525)
Langmuir. 2006 Jan 31;22(3):906-10. (PMID: 16430247)
J Control Release. 2010 Feb 15;141(3):300-2. (PMID: 19822177)
-
Contributed Indexing:
-
Keywords: amiodarone HCl; bioavailability enhancement; drug delivery; nanocrystals; pluronic F-127
-
Entry Date(s):
-
Date Created: 20220624 Latest Revision: 20230308
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9245605
-
DOI:
-
10.3390/pharmaceutics14061300
-
PMID:
-
35745871
-
The aim of this study was to improve the saturation solubility, dissolution profile and oral bioavailability of amiodarone hydrochloride (AMH), a highly lipophilic drug. Stabilizer (Pluronic F-127)-coated AMH nanocrystals (AMH-NCs) were developed by a combination of antisolvent precipitation and homogenization techniques. The optimized formulation comprised pluronic F-127 and AMH at the concentration of 4% and 2% w/v, respectively. The particle size (PS), zeta potential (ZP) and polydispersity index (PDI) of the optimized formulation was found to be 221 ± 1.2 nm, 35.3 mV and 0.333, respectively. The optimized formulation exhibited a rough surface morphology with particles in colloidal dimensions and a significant reduction in crystallinity of the drug. AMH-NCs showed a marked increase in the saturation solubility as well as rapid dissolution rate when compared with the AMH and marketed product. The stability study displayed that the formulation was stable for 3 months, with no significant change in the PS, ZP and PDI. The in vivo pharmacokinetic study demonstrated the ability of AMH-NCs to significantly (p < 0.05) improve the oral bioavailability (2.1-fold) of AMH in comparison with AMH solution, indicating that the production of AMH-NCs using a combination of antisolvent precipitation and homogenization techniques could enhance the bioavailability of the drug.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.